Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546149 | 0.85 | LMNA (0.39) | ALDH1A1MEN1KMT2ALMNAHTT | |
| SCHEMBL2546957 | 0.82 | NPC1 (0.43) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2546951 | 0.82 | BCHE (0.41) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL2541838 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ALMNAHTT | |
| SCHEMBL2538982 | 0.81 | USP2 (0.40) | ALDH1A1LMNA | |
| SCHEMBL2547266 | 0.80 | ABL1 (0.37) | TRPV1NPC1RAB9AHTTMAPT | |
| SCHEMBL2537528 | 0.79 | CSNK1D (0.38) | WNT3ATRPV1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2544861 | 0.78 | ACHE (0.36) | TRPV1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2540218 | 0.77 | USP2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL2546977 | 0.77 | TRPV1 (0.38) | TRPV1ALDH1A1LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
| EP-2318414-A2 | IMIDAZO [1,2-A] PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND USE AS MET INHIBITORS | Sanofi-Aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010007318-A2 | NOVEL IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | WNT3A 3409/4885TRPV1 3503/4885ALDH1A1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.